Watchlist

Watchlist
Akebia Therapeutics, Inc. (AKBA)
Akebia Therapeutics, Inc. (AKBA)
Your Daily Pharma Scoop: Celgene Upside, Erytech Tumbles, Novartis Neulasta Biosimilar
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Total Pharma Tracker subscribers get the full version with actionable ideas one day ea…
Akebia Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that the Company granted three newly-hired employees options to purchase an…
Your Daily Pharma Scoop: A Look At Sanofi, Ultragenyx Gets FDA Nod, Capricor Tumbles
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Sanofi Today we will discuss an art…
Akebia Therapeutics to Participate in Upcoming Investor Conferences
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will participat…
Your Daily Pharma Scoop: Neurocrine Has Upside, Dynavax Gets FDA Nod, Sage Soars
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Neurocrine Biosciences Today we will d…
Akebia Therapeutics Is A Buy With The Recent Stock Price Pullback
Akebia Therapeutics (NASDAQ: AKBA ) stock shows strong momentum with an over 71 percent gain this year so far. The company has a number of catalysts coming up including top-line data announcements related to its lead drug candidate vadadustat. The company also recently announced earnings los…
Akebia beats by $0.02, beats on revenue
Akebia (NASDAQ: AKBA ): Q3 EPS of -$0.49 beats by $0.02 . Revenue of $41.28M beats by $4.23M . Press Release More news on: Akebia Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,
Akebia Therapeutics Announces Third Quarter 2017 Financial Results
--Partner Mitsubishi Tanabe Pharma Corporation Initiates Phase 3 Development Program for Vadadustat in Japan-- Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypox…
Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Akebia Therapeutics , Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that the Company granted three newly-hired employees options to purchase an…
Your Daily Pharma Scoop: The First Trust NYSE Arca Biotechnology Index, Gilead's Single Pill, Acadia's New Trial
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: The First Trust NYSE Arca Biotechnology I…
Premarket analyst action - healthcare
Gilead Sciences (NASDAQ: GILD ) initiated with Market Perform rating by Oppenheimer. More news on: Gilead Sciences, Inc., FibroGen, Akebia Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more …
Akebia Therapeutics, Inc. (AKBA)